185 related articles for article (PubMed ID: 25863230)
1. High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia.
Friedlander AH; Chang TI; Hazboun RC; Garrett NR
J Oral Maxillofac Surg; 2015 Sep; 73(9):1735-40. PubMed ID: 25863230
[TBL] [Abstract][Full Text] [Related]
2. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Kunchur R; Need A; Hughes T; Goss A
J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
[TBL] [Abstract][Full Text] [Related]
3. A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study.
Hutcheson A; Cheng A; Kunchar R; Stein B; Sambrook P; Goss A
J Oral Maxillofac Surg; 2014 Aug; 72(8):1456-62. PubMed ID: 24793621
[TBL] [Abstract][Full Text] [Related]
4. A role for C-terminal cross-linking telopeptide (CTX) level to predict the development of bisphosphonate-related osteonecrosis of the jaws (BRONJ) following oral surgery?
O'Connell JE; Ikeagwani O; Kearns GJ
Ir J Med Sci; 2012 Jun; 181(2):237-42. PubMed ID: 22223192
[TBL] [Abstract][Full Text] [Related]
5. Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.
Awad ME; Sun C; Jernigan J; Elsalanty M
J Am Dent Assoc; 2019 Aug; 150(8):664-675.e8. PubMed ID: 31256803
[TBL] [Abstract][Full Text] [Related]
6. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
[TBL] [Abstract][Full Text] [Related]
7. Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw.
Peisker A; Raschke GF; Fahmy MD; Guentsch A; Roshanghias K; König KC; Schultze-Mosgau S
J Craniofac Surg; 2018 Mar; 29(2):e137-e140. PubMed ID: 29215447
[TBL] [Abstract][Full Text] [Related]
8. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Marx RE; Cillo JE; Ulloa JJ
J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
[TBL] [Abstract][Full Text] [Related]
9. Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.
Traboulsi-Garet B; Jorba-García A; Camps-Font O; Alves FA; Figueiredo R; Valmaseda-Castellón E
Clin Oral Investig; 2022 Mar; 26(3):2371-2382. PubMed ID: 35124731
[TBL] [Abstract][Full Text] [Related]
10. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers.
Fleisher KE; Welch G; Kottal S; Craig RG; Saxena D; Glickman RS
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):509-16. PubMed ID: 20674404
[TBL] [Abstract][Full Text] [Related]
11. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.
Lazarovici TS; Mesilaty-Gross S; Vered I; Pariente C; Kanety H; Givol N; Yahalom R; Taicher S; Yarom N
J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review.
Dal Prá KJ; Lemos CA; Okamoto R; Soubhia AM; Pellizzer EP
Int J Oral Maxillofac Surg; 2017 Feb; 46(2):151-156. PubMed ID: 27876532
[TBL] [Abstract][Full Text] [Related]
13. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study.
Salgueiro M; Stribos M; Zhang LF; Stevens M; Awad ME; Elsalanty M
EPMA J; 2019 Mar; 10(1):21-29. PubMed ID: 30984311
[TBL] [Abstract][Full Text] [Related]
14. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
Lee CY; Suzuki JB
Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
[TBL] [Abstract][Full Text] [Related]
15. Patients Receiving Parenteral Bisphosphonates for Malignant Disease and Having Developed an Atypical Femoral Fracture Are at Risk of Concomitant Osteonecrosis of the Jaw: An Evidence-Based Review.
Graves LL; Bukata SV; Aghazadehsanai N; Chang TI; Garrett NR; Friedlander AH
J Oral Maxillofac Surg; 2016 Dec; 74(12):2403-2408. PubMed ID: 27376180
[TBL] [Abstract][Full Text] [Related]
16. Salivary Biomarkers Associated With Bone Deterioration in Patients With Medication-Related Osteonecrosis of the Jaws.
Kolokythas A; Karras M; Collins E; Flick W; Miloro M; Adami G
J Oral Maxillofac Surg; 2015 Sep; 73(9):1741-7. PubMed ID: 25889372
[TBL] [Abstract][Full Text] [Related]
17. Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates.
Dioguardi M; Di Cosola M; Copelli C; Cantore S; Quarta C; Nitsch G; Sovereto D; Spirito F; Caloro GA; Cazzolla AP; Aiuto R; Cascardi E; Greco Lucchina A; Lo Muzio L; Ballini A; Mastrangelo F
Eur Rev Med Pharmacol Sci; 2023 Jul; 27(13):6359-6373. PubMed ID: 37458653
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
[TBL] [Abstract][Full Text] [Related]
19. Qualitative and quantitative analysis of the CTX in relation to the period of intake of bisphosphonates: A systematic review.
Milani M; Manenti RJ; Marcattili D; Marino R; Lomurno AP
J Biol Regul Homeost Agents; 2021; 35(3 Suppl. 1):219-227. PubMed ID: 34289682
[TBL] [Abstract][Full Text] [Related]
20. Experimental investigation of relationship between trauma and bisphosphonate-related osteonecrosis.
Agaçayak KS; Yuksel H; Atilgan S; Koparal M; Uçan MC; Ozgöz M; Yaman F; Atalay Y; Acikan I
Niger J Clin Pract; 2014; 17(5):559-64. PubMed ID: 25244263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
